Cytokinetics data confirm aficamten’s competitive profile, says Morgan Stanley

Morgan Stanley says full results of the aficamten Phase 3 SEQUOIA-HCM study, presented in a late-breaking session at the European Society of Cardiology’s Heart Failure meeting and simultaneously published in the NEJM, were more incremental following relatively detailed topline results in December. The full data from SEQUOIA-HCM remain supportive of aficamten’s competitive profile, but there remains uncertainty around whether aficamten can secure a less stringent REMS given similar percent change in LVEF as mavacamten, says the analyst, who has an Equal Weight rating and $70 price target on Cytokinetics shares.